Encouraging Phase 1 data on ZW191, an antibody-drug conjugate (ADC) targeting folate receptor-⍺ (FR⍺), presented at the AACR-NCI-EORTC ConferenceFirst patient dosed in Phase 1 clinical trial of ZW251 for the treatment of hepatocellular carcinomaAchievement of 25.0 million development milestone from Johnson & Johnson Innovative MedicineEarned royalties of 1.0 million based on Ziihera® net product sales by Jazz and BeOne Medicines for 3Q-2025Completed share repurchases of $22.7 million under share repurchas ...